Nabriva Therapeutics AG Company Profile (NASDAQ:NBRV)

Nabriva Therapeutics AG trades on the NASDAQ under the ticker symbol "NBRV."

Nabriva Therapeutics AG (NASDAQ:NBRV) posted its earnings results on Monday, August, 7th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($5.83) by $5.29. The business earned $1.05 million during the quarter, compared to analysts' expectations of $1.34 million. View Nabriva Therapeutics AG's Earnings History.

Nabriva Therapeutics AG is scheduled to release their next quarterly earnings announcement on Wednesday, November, 15th 2017. View Earnings Estimates for Nabriva Therapeutics AG.

7 equities research analysts have issued 1-year price objectives for Nabriva Therapeutics AG's shares. Their predictions range from $16.00 to $24.00. On average, they expect Nabriva Therapeutics AG's stock price to reach $20.14 in the next year. View Analyst Ratings for Nabriva Therapeutics AG.

Here are some recent quotes from research analysts about Nabriva Therapeutics AG stock:

• 1. Cantor Fitzgerald analysts commented, "Yesterday, after market close, Nabriva announced that Elyse Seltzer, M.D., is resigning as CMO effective 9/30/2017." (9/1/2017)
• 2. According to Zacks Investment Research, "Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. " (8/15/2017)
• 3. Needham & Company LLC analysts commented, "Nabriva reported 4Q16 financial results last week. Top- line results from LEAP1, first of two ongoing Phase 3 trials of lefamulin in Community Pneumonia (CABP), are expected 3Q17. This trial is evaluating both IV and oral formulations. Top-line results from LEAP2, which is evaluating only oral formulation, are expected 1Q18 (was 4Q17). We are favorably inclined based on Phase 2 IV skin infection trial, Phase 1 oral PK trial, and Phase 1 lung trial. We believe Solithera (Cempra) is unlikely to reach market, creating a vacuum in outpatient CABP space. If lefamulin is found to have particularly safe profile, drug may ultimately be useful not only in hospital setting for severe CABP , but also in much broader outpatient setting." (3/27/2017)
• 4. Wedbush analysts commented, "Nabriva recently reported that LEAP-1 has achieved 60% of its enrollment target, remaining on track to report data from both Ph 3 studies in 2H17 ' we believe both these readouts will be positive. In addition, we believe lefamulin's product profile possesses the key attributes required to take advantage of the commercial opportunity in CABP." (1/31/2017)

Some companies that are related to Nabriva Therapeutics AG include Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Cara Therapeutics (CARA), Agenus (AGEN), Corvus Pharmaceuticals (CRVS), NewLink Genetics Corporation (NLNK), Concert Pharmaceuticals (CNCE), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Puretech Health PLC (PRTC), Arbutus Biopharma Corporation (ABUS), Novavax (NVAX), Curis (CRIS), Codexis (CDXS), Protagonist Therapeutics (PTGX), Organovo Holdings (ONVO) and Horizon Discovery Group PLC (HZD).

Nabriva Therapeutics AG's management team includes the folowing people:

• Daniel D. Burgess, Independent Chairman of the Supervisory Board
• Colin Broom M.D., Chief Executive Officer
• Gary L. Sender, Chief Financial Officer
• William Q. Sargent, Vice President - Commercial Strategy and Investor Relations
• Robert L. Crotty, General Counsel
• Steven P. Gelone, Chief Development Officer
• Elyse G. Seltzer M.D., Chief Medical Officer
• Mark H.N. Corrigan M.D., Independent Member of the Supervisory Board
• Chau Quang Khuong, Independent Member of the Supervisory Board
• Charles A. Rowland Jr., Independent Member of the Supervisory Board

Nabriva Therapeutics AG's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vivo Capital LLC (147.80%), Omega Fund Management LLC (4.25%), Almanack Investment Partners LLC. (33.34%), Hillhouse Capital Management Ltd. (2.56%), Franklin Resources Inc. (12.86%) and EcoR1 Capital LLC (0.99%). Company insiders that own Nabriva Therapeutics AG stock include George Harrison Talbot, Hbm Healthcare Investments (Ca and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics AG.

Nabriva Therapeutics AG's stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Omega Fund Management LLC and Hillhouse Capital Management Ltd.. Company insiders that have sold Nabriva Therapeutics AG stock in the last year include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Insider Buying and Selling for Nabriva Therapeutics AG.

Nabriva Therapeutics AG's stock was purchased by a variety of institutional investors in the last quarter, including Almanack Investment Partners LLC., Royal Bank of Canada and Nationwide Fund Advisors. View Insider Buying and Selling for Nabriva Therapeutics AG.

Shares of Nabriva Therapeutics AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Nabriva Therapeutics AG stock can currently be purchased for approximately $9.19.